1. Market Research
  2. > Enterobacteriaceae Infections – Pipeline Review, H1 2013

Enterobacteriaceae Infections – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 154 pages

Enterobacteriaceae Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Enterobacteriaceae Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Enterobacteriaceae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterobacteriaceae Infections. Enterobacteriaceae Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Enterobacteriaceae Infections.
- A review of the Enterobacteriaceae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Enterobacteriaceae Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Enterobacteriaceae Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Enterobacteriaceae Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Enterobacteriaceae Infections - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Enterobacteriaceae Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Enterobacteriaceae Infections 9
Enterobacteriaceae Infections Therapeutics under Development by Companies 11
Enterobacteriaceae Infections Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Enterobacteriaceae Infections Therapeutics - Products under Development by Companies 21
Enterobacteriaceae Infections Therapeutics - Products under Investigation by Universities/Institutes 25
Companies Involved in Enterobacteriaceae Infections Therapeutics Development 26
Bioniche Life Sciences, Inc. 26
Genentech, Inc. 27
Dainippon Sumitomo Pharma Co., Ltd. 28
Nanotherapeutics, Inc. 29
Rib-X Pharmaceuticals, Inc. 30
Novartis AG 31
Cubist Pharmaceuticals, Inc. 32
Pfizer Inc. 33
Affinium Pharmaceuticals, Inc. 34
Nymox Pharmaceutical Corporation 35
Orchid Chemicals and Pharmaceuticals Ltd 36
Thallion Pharmaceuticals Inc. 37
Achaogen Inc. 38
Bharat Biotech International Limited 39
Shantha Biotechnics Limited 40
Evolva SA 41
GlycoVaxyn AG 42
Syntiron LLC 43
Sequoia Sciences, Inc. 44
Variation Biotechnologies, Inc. 45
TheraCarb Inc. 46
Phico Therapeutics Ltd. 47
AvidBiotics Corp. 48
Trana Discovery, Inc. 49
Cantab Biopharmaceuticals Limited 50
Enterobacteriaceae Infections - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
plazomicin - Drug Profile 57
GelVac - Drug Profile 59
RX-04 - Drug Profile 60
EV-021 - Drug Profile 61
ACE-920 - Drug Profile 62
EV-009 - Drug Profile 63
GVXN-SD133 - Drug Profile 64
CVD-1208S - Drug Profile 65
CVD-1902 - Drug Profile 66
M-10ZH09 - Drug Profile 67
Vi-CRM197 Glycoconjugated Vaccine - Drug Profile 69
ETEC Vaccine - Drug Profile 70
AMR-BAC-2 - Drug Profile 71
AMR-BAC-3 - Drug Profile 72
SLP-0907 - Drug Profile 73
SLP-0901 - Drug Profile 75
FB-1811 - Drug Profile 77
Oral Shigella Vaccine - Drug Profile 78
Fabl Inhibitor Program - Drug Profile 79
ETEC Adhesin-Based Vaccine - Drug Profile 80
SASPject PT3.X - Drug Profile 81
Anti-Bacterial Program - Drug Profile 82
Shigamabs - Drug Profile 83
Typhoid TT Vaccine - Drug Profile 85
Inactivated Whole Cell Shigella Flexneri 2a Vaccine - Drug Profile 86
OCID-5090 - Drug Profile 87
EV-035 - Drug Profile 88
RX-P792 - Drug Profile 89
Shigella Vaccine - Drug Profile 90
ExPEC Vaccine - Drug Profile 91
Gram-Negative Programme - Drug Profile 92
Antibacterial Program - Drug Profile 93
Gram Negative Antibacterial Programs - Drug Profile 94
ACHN-978 - Drug Profile 95
Snare Antibacterial For Gram Negative Infections - Drug Profile 96
Vi-CRM197 PCMV - Drug Profile 97
CB-027 - Drug Profile 98
(biapenem + RPX-7009) - Drug Profile 99
KPI-10 - Drug Profile 100
Salmonella Vaccine - Drug Profile 101
Drug For Escherichia coli - Drug Profile 102
Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 103
MVX-506 - Drug Profile 104
UPEC - Drug Profile 105
Novel Antibiotics - Drug Profile 106
NXC-4720 - Drug Profile 107
SM-295291 - Drug Profile 108
SM-369926 - Drug Profile 109
Metallo-Beta-Lactamase Inhibitors - Drug Profile 110
Bivalent Enteric Fever Conjugate Vaccine - Drug Profile 111
Vi-PspA Conjugate Vaccine - Drug Profile 112
OmpC-Vi Conjugate Vaccine - Drug Profile 113
Typhetec - Drug Profile 114
Thiolactomycin Analogues - Drug Profile 115
Antimicrobial Nanoparticles - Drug Profile 116
Vaccine Program - Drug Profile 117
Antibacterial Program - Drug Profile 119
CAP37-Derived Antimicrobial Peptides - Drug Profile 120
Human Cathelicidin LL-37 Derivatives - Drug Profile 121
SecATPase Inhibitors - Drug Profile 123
WRSs-2 Vaccine - Drug Profile 124
WRSs-3 Vaccine - Drug Profile 125
Dap-3 Polymyxin Analogs - Drug Profile 127
Enterotoxigenic Escherichia coli Vaccine - Drug Profile 128
Enterobacteriaceae Infections Therapeutics - Drug Profile Updates 129
Enterobacteriaceae Infections Therapeutics - Discontinued Products 135
Enterobacteriaceae Infections Therapeutics - Dormant Products 136
Enterobacteriaceae Infections - Product Development Milestones 138
Featured News and Press Releases 138
Appendix 148
Methodology 148
Coverage 148
Secondary Research 148
Primary Research 148
Expert Panel Validation 148
Contact Us 149
Disclaimer 149



List of Tables

Number of Products Under Development for Enterobacteriaceae Infections, H1 2013 14
Products under Development for Enterobacteriaceae Infections - Comparative Analysis, H1 2013 15
Number of Products under Development by Companies, H1 2013 17
Number of Products under Development by Companies, H1 2013 (Contd..1) 18
Number of Products under Development by Companies, H1 2013 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2013 21
Comparative Analysis by Late Stage Development, H1 2013 22
Comparative Analysis by Mid Clinical Stage Development, H1 2013 23
Comparative Analysis by Early Clinical Stage Development, H1 2013 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Development by Companies, H1 2013 (Contd..1) 27
Products under Development by Companies, H1 2013 (Contd..2) 28
Products under Development by Companies, H1 2013 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2013 30
Bioniche Life Sciences, Inc., H1 2013 31
Genentech, Inc., H1 2013 32
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 33
Nanotherapeutics, Inc., H1 2013 34
Rib-X Pharmaceuticals, Inc., H1 2013 35
Novartis AG, H1 2013 36
Cubist Pharmaceuticals, Inc., H1 2013 37
Pfizer Inc., H1 2013 38
Affinium Pharmaceuticals, Inc., H1 2013 39
Nymox Pharmaceutical Corporation, H1 2013 40
Orchid Chemicals and Pharmaceuticals Ltd, H1 2013 41
Thallion Pharmaceuticals Inc., H1 2013 42
Achaogen Inc., H1 2013 43
Bharat Biotech International Limited, H1 2013 44
Shantha Biotechnics Limited, H1 2013 45
Evolva SA, H1 2013 46
GlycoVaxyn AG, H1 2013 47
Syntiron LLC, H1 2013 48
Sequoia Sciences, Inc., H1 2013 49
Variation Biotechnologies, Inc., H1 2013 50
TheraCarb Inc., H1 2013 51
Phico Therapeutics Ltd., H1 2013 52
AvidBiotics Corp., H1 2013 53
Trana Discovery, Inc., H1 2013 54
Cantab Biopharmaceuticals Limited, H1 2013 55
Assessment by Monotherapy Products, H1 2013 56
Assessment by Combination Products, H1 2013 57
Assessment by Stage and Route of Administration, H1 2013 59
Assessment by Stage and Molecule Type, H1 2013 61
Enterobacteriaceae Infections Therapeutics - Drug Profile Updates 134
Enterobacteriaceae Infections Therapeutics - Discontinued Products 140
Enterobacteriaceae Infections Therapeutics - Dormant Products 141
Enterobacteriaceae Infections Therapeutics - Dormant Products (Contd..1) 142



List of Figures

Number of Products under Development for Enterobacteriaceae Infections, H1 2013 14
Products under Development for Enterobacteriaceae Infections - Comparative Analysis, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 20
Late Stage Products, H1 2013 22
Mid Clinical Stage Products, H1 2013 23
Early Clinical Stage Products, H1 2013 24
Discovery and Pre-Clinical Stage Products, H1 2013 25
Assessment by Monotherapy Products, H1 2013 56
Assessment by Combination Products, H1 2013 57
Assessment by Route of Administration, H1 2013 58
Assessment by Stage and Route of Administration, H1 2013 59
Assessment by Molecule Type, H1 2013 60
Assessment by Stage and Molecule Type, H1 2013 61

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.